NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Federal Government Invests $49.9 Million in STEMCELL Technologies Canada, Inc. - STEMCELL Technologies Canada, Inc. to build two new cutting-edge biomanufacturing facilities to produce critical inputs used in the development and manufacture of vaccines, therapeutics and diagnostic technologies - Stemcell.com
Federal Government Invests $49.9 Million in STEMCELL Technologies Canada, Inc.

 

NewswireTODAY - /newswire/ - Burnaby, British Columbia, Canada, 2025/03/20 - STEMCELL Technologies Canada, Inc. to build two new cutting-edge biomanufacturing facilities to produce critical inputs used in the development and manufacture of vaccines, therapeutics and diagnostic technologies - Stemcell.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Government of Canada continues to strengthen Canada’s dynamic industrial capabilities in the life sciences sector. We are expanding domestic biomanufacturing capacity, creating jobs and growing the economy, while also improving our ability to address future health needs and producing the next generation of medicines in our country.

Today, the Honourable Anita Anand, Minister of Innovation, Science and Industry, announced a $49.9 million investment through the Strategic Innovation Fund in STEMCELL Technologies Canada Inc. This investment will support the company’s $222 million project to establish large-scale production of essential inputs used to develop and manufacture vaccines, therapies and diagnostic technologies. It will also help create 460 jobs and 900 four-month co-op positions for students.

With this investment, STEMCELL will establish two new biomanufacturing facilities. This will enable the company to onshore the production of specialized inputs that are critical to the development and manufacturing of vaccines, therapies and diagnostics, as well as other innovative technologies, like tissue engineering, immunotherapy, and cell and gene therapies. These products are used by researchers and industrial partners here in Canada and around the globe, integrating Canada into global supply chains. With this funding, STEMCELL will build on the company’s status as a foundational part of British Columbia’s biomanufacturing and life sciences ecosystem.
Quotes

“British Columbia continues to rapidly grow its presence in the life sciences industry. With this investment, our government is bolstering Canada’s life sciences industry, increasing domestic capacity for key inputs for vaccines, therapeutics and diagnostic technologies, which are needed to keep Canadians safe and healthy and to export around the world. This partnership with STEMCELL will help grow our economy and create good, high-paying jobs for Canadians.”
The Honourable Anita Anand, Minister of Innovation, Science and Industry

“This investment in STEMCELL demonstrates our government’s commitment to fostering innovation in Canada’s life sciences sector. By supporting the development of cutting-edge biomanufacturing facilities, we are not only creating high-quality jobs but also positioning Canada as a leader in the production of critical inputs for vaccines, therapeutics and diagnostics. This project will strengthen our domestic capabilities and contribute to a more resilient health care system for all Canadians.”
Taleeb Noormohamed, Parliamentary Secretary to the Minister of Finance and Intergovernmental Affairs (Canada-U.S.)

“By supporting local innovation and expanding our biomanufacturing capacity, we are making strategic investments that will improve lives of Canadians, create good jobs here in British Columbia, and benefit the economic prosperity of our region for years to come. This investment in STEMCELL technologies represents the kind of innovation our community champions.”
The Honourable Terry Beech, Member of Parliament for Burnaby North Seymour

“This funding by the federal government addresses a gap in the raw materials required for large-scale manufacturing of vaccines, therapies and diagnostics, creating significant spillover effects across British Columbia and Canada. STEMCELL is committed to ensuring the Canadian life sciences industry continues to grow and improve the lives of people in Canada and around the world. Our Canadian health care system is only strong and successful when rooted in a robust life sciences industry that generates the diagnostic and therapeutic reagents and tools needed to treat disease.”
Dr. Allen Eaves, founder and CEO, STEMCELL Technologies Canada Inc.

Quick facts

• Canada’s Biomanufacturing and Life Sciences Strategy presents a vision to build a competitive, innovative and prosperous life sciences ecosystem that is able to protect Canadians against future pandemics and other health emergencies and to develop the next generation of medicines in our country.
• Since March 2020, over $2.3 billion has been invested in 41 projects to strengthen our country’s domestic biomanufacturing and life sciences capabilities to ensure Canadians have access to the most cutting-edge medical technologies to keep them safe and healthy.
• STEMCELL was founded in 1993 by CEO Dr. Allen Eaves when he needed a way to meet the demand for his standardized, cost-effective cell culture media. The company has since grown into a global biotechnology company, building essential products for developing and manufacturing stem cell technologies, vaccines, therapeutics and diagnostic technologies.
• Canada has a history of pioneering in this area; stem cells were discovered in the early 1960s through the work of Canadian scientists Dr. James Till and Dr. Ernest McCulloch at the University of Toronto.

Contacts
Myah Tomasi - Director of Communications, Office of the Minister of Innovation, Science and Industry
P: 343-543-7210 - E: Myah.Tomasi[.]FedDevOntario.gc.ca.

Media Relations
Innovation, Science and Economic Development Canada
E: media[.]ised-isde.gc.ca.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Federal Government Invests $49.9 Million in STEMCELL Technologies Canada, Inc.

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
STEMCELL Canada | The Government of Canada
Contact: Press Office - Stemcell.com 
public.relations[.]stemcell.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study
Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit BizJobs.com

Visit  Limelon Advertising, Co.





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)